title: A2Ablockade enhances anti-metastatic immune responses.
abstract: The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A2A/A2Badenosine receptors significantly reduced the metastatic potential of CD73+breast carcinomas and melanomas via both immunological and non-immunological mechanisms.
authors.affiliation: Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne; Parkville, VIC Australia.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Beavis
authors.affiliation: Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne; Parkville, VIC Australia.
authors.forename: Nicole
authors.initials: N
authors.lastname: Milenkovski
authors.affiliation: Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie et Institut du Cancer de Montréal; Montréal, QC Canada.
authors.forename: John
authors.initials: J
authors.lastname: Stagg
authors.affiliation: Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute; Herston, QLD Australia ; School of Medicine, University of Queensland, Herston, QLD Australia.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
authors.affiliation: Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; The University of Melbourne; Parkville, VIC Australia.
authors.forename: Phillip K
authors.initials: PK
authors.lastname: Darcy
keywords: CD73; adenosine; adenosine receptors; cancer; immunotherapy; metastases